The hydrogel speeds up wound healing and improves tissue repair.
June 2025 in “Revista Ciencia Multidisciplinaria CUNORI” Early intervention is crucial for managing blood clotting issues in pregnant women with COVID-19.
September 2023 in “Journal of the American Academy of Dermatology” 1 citations
,
September 2001 in “PubMed” Acitretin treats severe skin conditions but requires careful monitoring due to serious side effects.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Targeting cholesterol, fatty acids, fibrosis, and mast cells may help treat CCCA.
37 citations
,
August 2016 in “Clinical, Cosmetic and Investigational Dermatology” The document concludes that better treatments for CCCA are needed and more research is required to understand its causes related to hairstyling and genetics.
February 2026 in “Macromolecular Bioscience” Keratin-based hydrogels with calcium are effective for delivering anti-fibrotic drugs.
2 citations
,
September 2015 in “Journal of the Egyptian Women's Dermatologic Society (Print)” Different centrifugation speeds change the quality of platelet-rich plasma.
11 citations
,
January 2009 in “World Journal of Gastroenterology” A woman with both Cronkhite-Canada syndrome and myelodysplastic syndrome improved significantly with corticosteroid treatment.
60 citations
,
October 2009 in “Dermatology” Alopecia areata may appear differently depending on the individual's type of hair loss and scalp condition.
7 citations
,
July 2019 in “The Journal of Dermatology” Terbinafine effectively treated kerion celsi despite disrupted immune responses.
50 citations
,
July 2015 in “Journal of the American Academy of Dermatology” Using 2.5 mg/mL triamcinolone acetonide is effective for hair growth in alopecia areata with fewer side effects.
February 2025 in “American Journal of Biomedical Science & Research” A rare combination of hair loss and excessive fine hair growth was found in celiac disease patients.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine may be effective for treating ashy dermatosis.
8 citations
,
July 2018 in “The Journal of Dermatology” Current corticosteroid pulse therapy is not very effective for severe rapidly progressive alopecia areata.
10 citations
,
February 2018 in “Royal Society Open Science” Modified wheat protein in shampoo repairs and smooths damaged hair effectively.
14 citations
,
February 1991 in “FEBS Letters” Introducing the rat OTC gene partially corrected OTC deficiency in mice.
March 2022 in “Authorea (Authorea)” Chemotherapy for leukemia led to full hair regrowth in a child with alopecia totalis.
November 2025 in “Biomedicines” Hypochlorous acid is a safe, effective antimicrobial with potential in various medical fields, but more research is needed to improve its stability and use.
September 2019 in “Rheumatology advances in practice” Diagnosing and treating rapidly worsening lung disease is difficult and requires better guidelines and understanding.
100 citations
,
September 2016 in “Clinical transplantation/Clinical transplantation.” Voriconazole can cause serious side effects, especially in long-term use.
13 citations
,
February 2019 in “Türk oftalmoloji dergisi” New treatments for chronic central serous chorioretinopathy show promise in preventing permanent vision loss.
1 citations
,
May 2024 in “Skin Appendage Disorders” Hair regrowth was achieved using 5-Fluorouracil and Bleomycin for scalp atrophy caused by corticosteroids.
11 citations
,
June 2017 in “Journal of cell science” AGD1's PH domain is essential for its role in root hair growth and polarity.
January 2022 in “Yonsei Medical Journal” Spironolactone helps reduce fluid in the eye in Central Serous Chorioretinopathy, but doesn't improve vision and recurrence is common.
Water and fatty acids affect hair's surface differently based on hair damage, and models can help understand hair-cosmetic interactions.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” The document discusses the submission of a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), a PROTAC protein degrader targeting the estrogen receptor, by Arvinas and Pfizer. This submission is based on positive results from the Phase 3 VERITAC-2 trial and marks a significant milestone as vepdegestrant is anticipated to be the first FDA-approved PROTAC degrader. PROTACs, a novel class of molecules, selectively degrade disease-causing proteins and offer advantages over traditional small molecule inhibitors, such as mitigating off-target effects and overcoming drug resistance. Despite concerns about their large molecular weight and drug-like properties, recent clinical results have been promising. The success of PROTACs has inspired the development of other chimeric molecules for therapeutic applications.
9 citations
,
January 2008 in “Medical mycology” A dog's skin infection caused by the fungus Chaetomium globosum was effectively treated with ketoconazole.
65 citations
,
November 2016 in “Journal of The American Academy of Dermatology” The document concludes that early recognition and treatment of primary cicatricial alopecia is crucial to prevent permanent hair loss.
2 citations
,
September 2011 in “Revista de Ciências Farmacêuticas Básica e Aplicada” The chili pepper shampoo was safe and well-liked by volunteers.